Glenmark launches unique fixed dose combination drug for Diabetes

The drug firm said it has launched the same under two brand names - Remo MV and Remozen MV.

266
Laboratory Diabetes Blood sugar
Picture: Pixabay

Last Updated on October 28, 2021 by The Health Master

Glenmark Pharmaceuticals said it has become the first company in the world to launch a unique fixed dose combination (FDC) drug for diabetes in India.

The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin.

The combination contains Remogliflozin (100 mg), Vildagliptin (50 mg) and Metformin (500/1000 mg) in a fixed dose to be taken twice daily to improve glycemic control in patients.

The drug firm said it has launched the same under two brand names – Remo MV and Remozen MV.

Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination (FDC) and India is the first country to get access to this FDC drug,” the drug firm noted in a statement.

While the average daily cost of therapy of existing brands in the same drug category is around Rs 75, Glenmark’s product has been launched at a price of Rs 16.50 per tablet, to be taken twice daily; which amounts to Rs 33 as the per day cost of therapy.

Diabetes is a key focus area for Glenmark and we have been at the forefront in providing access to the latest treatment options to diabetes patients in India,” Glenmark India Formulations Group Vice President and Business Head Alok Malik stated.

The company had received approval from the DCGI for manufacturing and marketing this fixed dose combination in September 2021.

Globally, SGLT2 inhibitors and DPP4 inhibitors are emerging as the preferred treatment option for the management of Type 2 diabetes.

According to the International Diabetes Federation (IDF), around 7.7 crore adults are living with diabetes as of 2019.

Notifications: New Drugs, FDC, Clinical Trial

Other details about New Drugs, FDCs, Clinical trial

AstraZeneca launches Clinical Trial Data division in India

MSN Labs launches Empagliflozin tablets for diabetes in India

Intas launches the World’s first SB-100mg Itraconazole

West launches 0.5mL standard syringe device in India

Biocon launches Everolimus tablets in US

Natco Pharma launches higher strength Anti Cancer generic drug

Govt extends validity of licences of Distilleries to mfr Hand Sanitizer

NPPA sets up PMRUs in 19 states and Union Territories

APIs Price hike impacts Indian Pharma Industry badly

USFDA gives approval for Eye Injection to teat vision loss

EU Regulator starts real-time review of anti viral drug Molnupiravir

Designing a better bottle for Eye Drops is need of the…

Ministry: Decriminalising possession of small amount of drugs for personal use

Bharat Bitoech is waiting for DCGI nod for children’s C-19 Vaccine

Procedure to obtain license for manufacturing of Homoeopathic Medicines

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news